A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT05395481 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

176

Enrollment

INDUSTRY

Sponsor class

Conditions

Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)

Interventions

DRUG: LY3849891
DRUG: Placebo

Sponsor

Eli Lilly and Company